Molecular Partners (NASDAQ:MOLN) Stock Price Down 5.9%

Shares of Molecular Partners AG (NASDAQ:MOLN) were down 5.9% during mid-day trading on Thursday . The company traded as low as $3.65 and last traded at $3.65. Approximately 2,068 shares changed hands during mid-day trading, a decline of 85% from the average daily volume of 13,668 shares. The stock had previously closed at $3.88.

Molecular Partners Stock Down 5.9 %

The firm’s 50-day moving average is $4.08 and its 200-day moving average is $4.25. The company has a market cap of $132.75 million, a PE ratio of -1.72 and a beta of 0.77.

Molecular Partners (NASDAQ:MOLN) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($0.68) earnings per share (EPS) for the quarter. Molecular Partners had a negative net margin of 885.11% and a negative return on equity of 31.10%. The company had revenue of $1.17 million for the quarter. As a group, equities research analysts anticipate that Molecular Partners AG will post -1.96 EPS for the current fiscal year.

Molecular Partners Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.